Integra LifeSciences Aims To Shutter Two Plants, Discontinue Low-Growth Products
This article was originally published in The Gray Sheet
Executive Summary
The plans are part of a strategy to consolidate manufacturing operations while prioritizing fast-growing, high-margin regenerative medicine products.
You may also be interested in...
Extremities, Emerging Markets Continue To Top M&A Ortho Interest
With hip and knee joint markets still registering slow to modest growth, orthopedic companies looking to add bulk to their bottom line through mergers and acquisitions have pursued two distinct directions – the extremities and emerging markets.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.